18594010	238	Koivunen JP	EML4-ALK fusion gene and efficacy of an ALK kinase inhibitor in lung cancer.	Clinical cancer research 	2008	213
19147828	238	Martelli MP	EML4-ALK rearrangement in non-small cell lung cancer and non-tumor lung tissues.	The American journal of pathology	2009	78
19737969	238	Lin E	Exon array profiling detects EML4-ALK fusion in breast, colorectal, and non-small cell lung cancers.	Molecular cancer research 	2009	79
20009909	238	Solomon B	ALK gene rearrangements: a new therapeutic target in a molecularly defined subset of non-small cell lung cancer.	Journal of thoracic oncology 	2009	62
20418096	238	Sasaki T	The biology and treatment of EML4-ALK non-small cell lung cancer.	European journal of cancer	2010	101
20979473	238	Choi YL	EML4-ALK mutations in lung cancer that confer resistance to ALK inhibitors.	The New England journal of medicine	2010	271
21030459	238	Sasaki T	The neuroblastoma-associated F1174L ALK mutation causes resistance to an ALK kinase inhibitor in ALK-translocated cancers.	Cancer research	2010	98
21288922	238	Shaw AT	Targeting anaplastic lymphoma kinase in lung cancer.	Clinical cancer research 	2011	48
21502504	238	Katayama R	Therapeutic strategies to overcome crizotinib resistance in non-small cell lung cancers harboring the fusion oncogene EML4-ALK.	Proceedings of the National Academy of Sciences of the United States of America	2011	147
21575866	238	Sakamoto H	CH5424802, a selective ALK inhibitor capable of blocking the resistant gatekeeper mutant.	Cancer cell	2011	114
24887559	238	Kodama T	Selective ALK inhibitor alectinib with potent antitumor activity in models of crizotinib resistance.	Cancer letters	2014	28
25721120	238	Pekar-Zlotin M	Fluorescence in situ hybridization, immunohistochemistry, and next-generation sequencing for detection of EML4-ALK rearrangement in lung cancer.	The oncologist	2015	20
26544515	238	Nilsson RJ	Rearranged EML4-ALK fusion transcripts sequester in circulating blood platelets and enable blood-based crizotinib response monitoring in non-small-cell lung cancer.	Oncotarget	2016	14
26829319	238	Zheng GX	Haplotyping germline and cancer genomes with high-throughput linked-read sequencing.	Nature biotechnology	2016	34
19234440	1956	Inamura K	EML4-ALK lung cancers are characterized by rare other mutations, a TTF-1 cell lineage, an acinar histology, and young onset.	Modern pathology 	2009	103
19667264	1956	Shaw AT	Clinical features and outcome of patients with non-small-cell lung cancer who harbor EML4-ALK.	Journal of clinical oncology 	2009	383
20183914	1956	Takahashi T	Clinicopathologic features of non-small-cell lung cancer with EML4-ALK fusion gene.	Annals of surgical oncology	2010	80
20551945	1956	Janku F	Targeted therapy in non-small-cell lung cancer--is it becoming a reality?	Nature reviews. Clinical oncology	2010	61
20624322	1956	Zhang X	Fusion of EML4 and ALK is associated with development of lung adenocarcinomas lacking EGFR and KRAS mutations and is correlated with ALK expression.	Molecular cancer	2010	79
20855837	1956	Sun Y	Lung adenocarcinoma from East Asian never-smokers is a disease largely defined by targetable oncogenic mutant kinases.	Journal of clinical oncology 	2010	93
21258415	1956	Normant E	The Hsp90 inhibitor IPI-504 rapidly lowers EML4-ALK levels and induces tumor regression in ALK-driven NSCLC models.	Oncogene	2011	46
21483012	1956	Paik PK	Clinical characteristics of patients with lung adenocarcinomas harboring BRAF mutations.	Journal of clinical oncology 	2011	115
21791641	1956	Sasaki T	A novel ALK secondary mutation and EGFR signaling cause resistance to ALK kinase inhibitors.	Cancer research	2011	157
21862980	1956	Mok TS	Personalized medicine in lung cancer: what we need to know.	Nature reviews. Clinical oncology	2011	40
22194472	1956	Ju YS	A transforming KIF5B and RET gene fusion in lung adenocarcinoma revealed from whole-genome and transcriptome sequencing.	Genome research	2012	122
22235099	1956	Doebele RC	Mechanisms of resistance to crizotinib in patients with ALK gene rearranged non-small cell lung cancer.	Clinical cancer research 	2012	213
22843788	1956	Tanizaki J	Activation of HER family signaling as a mechanism of acquired resistance to ALK inhibitors in EML4-ALK-positive non-small cell lung cancer.	Clinical cancer research 	2012	46
23052255	1956	Suehara Y	Identification of KIF5B-RET and GOPC-ROS1 fusions in lung adenocarcinomas through a comprehensive mRNA-based screen for tyrosine kinase fusions.	Clinical cancer research 	2012	35
23341890	1956	Li Y	Clinical significance of EML4-ALK fusion gene and association with EGFR and KRAS gene mutations in 208 Chinese patients with non-small cell lung cancer.	PloS one	2013	41
23931927	1956	Gridelli C	ALK inhibitors in the treatment of advanced NSCLC.	Cancer treatment reviews	2014	34
24199682	1956	Yamaguchi N	Dual ALK and EGFR inhibition targets a mechanism of acquired resistance to the tyrosine kinase inhibitor crizotinib in ALK rearranged lung cancer.	Lung cancer	2014	23
25468140	1956	Kalia M	Biomarkers for personalized oncology: recent advances and future challenges.	Metabolism	2015	32
25629635	1956	Wu C	High Discrepancy of Driver Mutations in Patients with NSCLC and Synchronous Multiple Lung Ground-Glass Nodules.	Journal of thoracic oncology 	2015	16
17625570	27436	Soda M	Identification of the transforming EML4-ALK fusion gene in non-small-cell lung cancer.	Nature	2007	1018
